Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247699 | 0.86 | ACACB (0.37) | HCRTR2HCRTR1ACACBMGLLCYP11B1 | |
| SCHEMBL3924934 | 0.82 | ACACB (0.47) | HCRTR2HCRTR1ACACBMGLLGRM5 | |
| SCHEMBL22637463 | 0.79 | MGLL (0.39) | HCRTR2HCRTR1ACACBMGLLCYP11B1 | |
| SCHEMBL30117145 | 0.79 | CYP11B1 (0.41) | HCRTR2HCRTR1ACACBMGLLCYP11B1 | |
| SCHEMBL25417413 | 0.79 | CYP11B1 (0.41) | HCRTR2HCRTR1ACACBMGLLCYP11B1 | |
| SCHEMBL29867993 | 0.76 | LOX (0.47) | HCRTR2HCRTR1ACACBGRM5CLK4 | |
| SCHEMBL447719 | 0.76 | LOX (0.47) | HCRTR2HCRTR1ACACBGRM5CLK4 | |
| SCHEMBL4321088 | 0.74 | KDM4E (0.40) | ACACBCYP11B1CYP11B2 | |
| SCHEMBL25259201 | 0.74 | JAK2 (0.35) | HCRTR2HCRTR1ACACBMGLLCYP11B1 | |
| SCHEMBL27958617 | 0.73 | GRM4 (0.39) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-28 | — | — | US | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4172140-A1 | CYCLOBUTYL-UREA DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4143165-A1 | SPIROUREA DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-115702141-A | Cyclobutyl-urea derivatives | 爱杜西亚药品有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021260090-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021219594-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | HCRTR2 4014/4885HCRTR1 4100/4885ACACB 556/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | HCRTR2 4014/4885HCRTR1 4100/4885ACACB 556/4885 |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | KCNA4, KCNMB4, KCNA7 | HCRTR2 1838/4885HCRTR1 1798/4885ACACB 3648/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HCRTR2 4014/4885HCRTR1 4100/4885ACACB 556/4885 |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | HCRTR2 2080/4885HCRTR1 1510/4885ACACB 3931/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | HCRTR2 4014/4885HCRTR1 4100/4885ACACB 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.